| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:51 UTC |
|---|
| HMDB ID | HMDB0015061 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Phenoxybenzamine |
|---|
| Description | Phenoxybenzamine, also known as dibenyline or fenossibenzamina, belongs to the class of organic compounds known as phenylmethylamines. Phenylmethylamines are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine. Phenoxybenzamine is a drug which is used for the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension. Phenoxybenzamine is a very strong basic compound (based on its pKa). It is also used in complex regional pain syndrome (CRPS) type 1 due to its anti-adrenergic affects. Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors. This results in further vasodilation, pupil constriction, an increase in GI tract motility and secretions, and glycogen synthesis. This causes vasodilatation in blood vessels, due to its antagonistic effect at the alpha-1 adrenoceptor found in the walls of blood vessels, resulting in a drop in blood pressure. |
|---|
| Structure | CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1 InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Fenossibenzamina | HMDB | | Dibenyline | HMDB | | Hydrochloride, phenoxybenzamine | HMDB | | Dibenylene | HMDB | | Dibenziran | HMDB | | Goldshield brand OF phenoxybenzamine hydrochloride | HMDB | | Link brand OF phenoxybenzamine hydrochloride | HMDB | | Esparma brand OF phenoxybenzamine hydrochloride | HMDB | | Dibenzyline | HMDB | | Phenoxybenzamine hydrochloride | HMDB | | Wellspring brand OF phenoxybenzamine hydrochloride | HMDB | | Dibenzylin | HMDB | | Dibenzyran | HMDB |
|
|---|
| Chemical Formula | C18H22ClNO |
|---|
| Average Molecular Weight | 303.826 |
|---|
| Monoisotopic Molecular Weight | 303.138992038 |
|---|
| IUPAC Name | benzyl(2-chloroethyl)(1-phenoxypropan-2-yl)amine |
|---|
| Traditional Name | phenoxybenzamine |
|---|
| CAS Registry Number | 59-96-1 |
|---|
| SMILES | CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3 |
|---|
| InChI Key | QZVCTJOXCFMACW-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylmethylamines. Phenylmethylamines are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Phenylmethylamines |
|---|
| Direct Parent | Phenylmethylamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzylamine
- Phenoxy compound
- Phenol ether
- Phenylmethylamine
- Alkyl aryl ether
- Aralkylamine
- Tertiary aliphatic amine
- Tertiary amine
- Ether
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organic nitrogen compound
- Amine
- Alkyl halide
- Alkyl chloride
- Hydrocarbon derivative
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 39 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.01 g/L | Not Available | | LogP | 4.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.01 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.5294 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.08 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 25.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1893.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 360.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 198.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 191.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 130.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 619.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 593.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 89.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1266.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 507.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1399.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 361.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 459.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 254.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 169.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Phenoxybenzamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-7930000000-384c032e9b77eb66c749 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Phenoxybenzamine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 10V, Positive-QTOF | splash10-0udi-4029000000-388f1c34ddb95b1ee009 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 20V, Positive-QTOF | splash10-0006-9231000000-ec96011b63bed09eb912 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 40V, Positive-QTOF | splash10-0006-9000000000-56a30aa5b92d840f5281 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 10V, Negative-QTOF | splash10-0udi-4029000000-387751e302c4f69be132 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 20V, Negative-QTOF | splash10-0006-9121000000-8f4d9ec9ea1e13488b14 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 40V, Negative-QTOF | splash10-0006-9000000000-6ea07a460948ae16252b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 10V, Positive-QTOF | splash10-0udi-0009000000-0ae6b7497ff7182fb842 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 20V, Positive-QTOF | splash10-0006-9702000000-5ffc7c8dda8bb19ba742 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 40V, Positive-QTOF | splash10-0006-9200000000-209610c0ebfc4d88a446 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 10V, Negative-QTOF | splash10-001i-9100000000-4d9bc979eb54eab7bcac | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 20V, Negative-QTOF | splash10-000x-9000000000-89136960ac0373c92e2c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phenoxybenzamine 40V, Negative-QTOF | splash10-0006-9000000000-f58b743d198c36a0fc6f | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. [PubMed:11395517 ]
- Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551-4. [PubMed:88984 ]
|
|---|